RebeccaB.KlisovicMD

Oncology • Cleveland, OH

Hematologic Oncology

Assistant CMIO UH Seidman Cancer Professor - Hematology & Oncology

Join to view full profile

Dr. Klisovic is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klisovic's full profile

Already have an account?

Office
UH Cleveland Medical Center
11100 Euclid Ave Department of Medicine-Hematology and Oncology
Cleveland, OH 44106
Phone+1 216-844-3951

Fax+1 216-844-5234

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2001 - 2004
University of North Carolina HospitalsResidency, Internal Medicine, 1997 - 2000
Ohio State University College of MedicineClass of 1997
Case Western Reserve UniversityBS, Biomedical Engineering, 1989 - 1993

Certifications & Licensure

OH State Medical License 2001 - 2025
GA State Medical License 2017 - 2022
NC State Medical License 1998 - 2001
American Board of Internal Medicine Medical Oncology
EpicPhysician Builder

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Combination of GTI-2040 and Cytarabine in the Treatment of Refractory and Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2007 Aug 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
Completed
Phase 1
Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2011 Jan 20
Completed
Phase 1
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) Start of enrollment: 2013 Apr 01
Terminated
Phase 2
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Sep 17
Completed
Phase 1
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
CAR-T Long Term Follow Up (LTFU) Study Start of enrollment: 2015 Nov 02
Recruiting
Phase 3
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2016 Mar 01
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

1404 citations
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Richard Stone, Sumithra J. Mandrekar, Ben L. Sanford, Kristina Laumann, Susan Geyer
The New England Journal of Medicine. 2017-06-23
101 citations
The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.
Susan P. Whitman, Shujun Liu, Tamara Vukosavljevic, Laura J. Rush, Li Yu
Blood. 2005-07-01
44 citations
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
William Blum, Mitch A. Phelps, Rebecca B. Klisovic, Darlene M. Rozewski, Wenjun Ni
Haematologica. 2010-07-01

Lectures

Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Authored Content

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

OncLive® Presents State of the Science Summit™ on Hematologic MalignanciesOctober 31st, 2019
Turning Points: Together in Sickness, Married in HealthAugust 1st, 2016
Bone-Marrow Donor Travels from Israel for Wedding of Transplant RecipientApril 29th, 2016
Join now to see all